8
Participants
Start Date
November 10, 2023
Primary Completion Date
October 25, 2024
Study Completion Date
October 25, 2024
AGALSIDASE BETA (GZ419828)
Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
Acetaminophen
Tablet or solution; Oral
Diphenhydramine
Tablet or solution; Oral
Dexamethasone
Tablet or solution; Oral
Montelukast
Tablet or chewable tablet or oral granules; Oral
Loratadine
Tablet or chewable tablet; Oral
Cetirizine
Tablet or oral solution; Oral
Fexofenadine
Tablet or oral suspension; Oral
Metropolitan Hospital Center Site Number : 1004, New York
Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002, Fairfax
Infusion Associates Site Number : 1001, Grand Rapids
UCLA Medical Center Site Number : 1003, Santa Monica
Emory University School of Medicine Site Number : 1005, Atlanta
Lead Sponsor
Sanofi
INDUSTRY